0

Peroxiredoxin I Contributes to TRAIL Resistance Through Suppression of Redox-Sensitive Caspase Activation in Human Hepatoma Cells

In-Sung Song, Sun-Uk Kim, Nang-Su Oh, Jiyoung Kim, Dae-Yeul Yu, Song Mei Huang, Jin-Man Kim, Dong-Seok Lee, Nam-Soon Kim

Carcinogenesis. 2009 Jul;30(7):1106-14.

PMID: 19406930

Abstract:

Reactive oxygen species (ROS) have been implicated in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) resistance of many cancers. We evaluated the role of peroxiredoxin (Prx) I in TRAIL resistance governed by coupling of nicotinamide adenosine dinucleotide phosphate oxidase (Nox)-derived ROS signaling with the p38 mitogen-activated protein kinase (MAPK)/caspase-signaling cascade in liver cancer cells. Upregulated Prx I expression was found in neoplastic regions of human patient liver, and Prx I knockdown resulted in accelerated TRAIL-induced cell death in SK-Hep-1 human hepatoma cells. The TRAIL cytotoxicity by Prx I knockdown was dependent on activation of caspase-8/3 cascades, which was ablated by addition of inhibitors for p38 MAPK, ROS or Nox, suggesting the association with Nox-driven redox signaling. Furthermore, we found that Nox4 was constitutively expressed in both SK-Hep-1 cells and tumor regions of patient livers, knockdown of Nox4 expression could alleviate ROS generation and TRAIL-mediated cytotoxicity. In accordance with previous findings, increased activation of both p38 MAPK and caspase cascades by Prx I knockdown was inhibited by either Nox4 knockdown or SB203580 addition. Collectively, these data suggest that Prx I functions to block propagation of Nox-derived ROS signaling to the p38 MAPK/caspase/cell death cascade during TRAIL treatment and also provides a molecular mechanism by which Prx I contributes to TRAIL resistance in liver cancers.

Chemicals Related in the Paper:

Catalog Number Product Name Structure CAS Number Price
IAR4241055 Peroxiredoxin 1 human Peroxiredoxin 1 human Price
qrcode